What are the significant drug interactions and precautions for oseltamivir (Tamiflu)?

Oseltamivir Drug Interactions

Oseltamivir has minimal clinically significant drug interactions, with the notable exception of probenecid, which doubles oseltamivir carboxylate exposure but requires no dose adjustment due to the drug's wide safety margin. 1

Key Drug Interactions

Live Attenuated Influenza Vaccine (LAIV)

• Do not administer LAIV within 2 weeks before or 48 hours after oseltamivir unless medically indicated 1, 2
• Oseltamivir can inhibit replication of live vaccine virus, potentially reducing vaccine effectiveness
• The interference window extends with:
  • Oseltamivir/zanamivir: 48 hours after last dose
  • Peramivir: 5 days after last dose
  • Baloxavir: 17 days after last dose 2
• Inactivated influenza vaccines can be administered at any time relative to oseltamivir use 1

Probenecid

• Probenecid increases oseltamivir carboxylate exposure approximately 2-fold by blocking active anionic tubular secretion in the kidney 1, 3
• No dose adjustment required despite this interaction due to oseltamivir's wide safety margin 1
• This interaction actually validates that oseltamivir is secreted via the organic anion pathway 3

Medications WITHOUT Significant Interactions

The following medications have been studied and show no pharmacokinetic interactions with oseltamivir 1:

• Amoxicillin
• Acetaminophen
• Aspirin
• Cimetidine
• Antacids (magnesium/aluminum hydroxides, calcium carbonates)
• Warfarin (per FDA label)

Warfarin - Conflicting Evidence

The FDA label states no interaction exists 1, but clinical vigilance is warranted:

• A 2010 randomized crossover study in 20 warfarinized patients found oseltamivir had no effect on warfarin pharmacokinetics or pharmacodynamics (INR, factor VIIa) 4
• However, a 2017 case report documented INR elevation in an 83-year-old woman on warfarin after starting oseltamivir 5
• Practical approach: While routine INR monitoring is not required based on the controlled trial data, consider monitoring INR in elderly patients or those with unstable anticoagulation when initiating oseltamivir 5

Immunosuppressants

• No interaction with cyclosporine, mycophenolate, or tacrolimus in renal transplant patients 6
• A small (13%) increase in tacrolimus trough levels was observed but is not clinically significant 6
• Oseltamivir is safe to use in transplant recipients without dose adjustments

Why Interactions Are Minimal

Oseltamivir's pharmacokinetic profile explains its low interaction potential 1:

1. Metabolism: Converted to active oseltamivir carboxylate by hepatic esterases (not CYP450 enzymes)
2. Protein binding: Low protein binding minimizes displacement interactions
3. Excretion: Eliminated by glomerular filtration and anionic tubular secretion
4. Not a CYP450 substrate: Neither oseltamivir nor its carboxylate metabolite interact with P450 oxidases or glucuronyl transferases 1

Special Populations Requiring Dose Adjustment

Renal Impairment

For creatinine clearance 10-30 mL/min 7:

• Treatment: 75 mg once daily for 5 days (instead of twice daily)
• Prophylaxis: 30 mg once daily OR 75 mg every other day for 10 days after exposure

No dosing recommendations available for patients on dialysis 8

Hepatic Impairment

• Oseltamivir use has not been studied in hepatic dysfunction 8
• Use with caution, though hepatic metabolism is via esterases rather than complex pathways

Critical Pitfalls to Avoid

1. Don't assume all antivirals have the same vaccine interaction window - baloxavir requires 17 days separation from LAIV versus 48 hours for oseltamivir 2

2. Don't routinely adjust doses for probenecid co-administration - despite doubled exposure, the safety margin allows continued standard dosing 1

3. Don't extrapolate renal dosing to dialysis patients - no validated dosing exists for this population 8

4. Don't confuse lack of CYP450 interactions with complete absence of drug interactions - the renal secretion pathway can still be affected by drugs like probenecid 3